Diabetic CVD--soluble epoxide hydrolase as a target.
The incidence of cardiovascular diseases remains high in diabetic patients despite the optimization of blood glucose control and the therapeutic management of risk factors. One emerging promising pharmacological approach that may help to prevent the development of diabetic cardiovascular complications is to improve endothelial function through the restoration of the bioavailability of epoxyeicosatrienoic acids (EETs). EETs are crucial eicosanoid signaling molecules synthesized by cytochrome P450 epoxygenases in the vascular endothelium and in pancreatic islets. EETs promote vasodilatation and display attractive anti-inflammatory and anti-aggregating actions together with potent effects on insulin release and sensitivity. In animal models of insulin-resistance and diabetes, a decrease in EET availability has been reported, and is a deleterious mechanism that probably contributes to multiple metabolic, cardiovascular and renal disorders in this setting. Moreover, increasing experimental evidence suggest that the use of soluble epoxide hydrolase (sEH) inhibitors, which prevent EET degradation, is a promising pharmacological approach to prevent endothelial dysfunction and to protect against target organ damage in metabolic diseases. This review presents evidence that the EET pathway is disturbed from the early stages of metabolic diseases, and analyzes the potential contribution of EETs impairment to the progression of cardiovascular diseases associated with diabetes. Pathophysiological and therapeutic perspectives are thereafter discussed, including the necessity to demonstrate the role of EET pathway alterations in endothelial dysfunction associated with diabetes in human, and the interest of sEH inhibitors to prevent the development of diabetic cardiovascular complications, with the expected result of improving patients' health.
Department of Pharmacology, Rouen University Hospital, Rouen, France.
Aurelien
A
Lorthioir
Dominique
D
Guerrot
Robinson
R
Joannides
Jeremy
J
Bellien
D000818:Animals; D002318:Cardiovascular Diseases / Q000150:complications* / Q000628:therapy*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000628:therapy*; D016503:Drug Delivery Systems; D004851:Epoxide Hydrolases / Q000737:chemistry / Q000378:metabolism*; D006801:Humans; D011480:Protease Inhibitors / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000737:chemistry; D012995:Solubility
D011480:Protease Inhibitors; D011994:Recombinant Proteins; D004851:Epoxide Hydrolases